From the Service de Cardiologie, Pôle Cardio-Vasculaire et Pulmonaire (P.d.G., M.F., A.D.P., C.G., N.L., C.B.) and Service des Explorations Fonctionnelles Cardio-vasculaires, Pôle Imagerie et Explorations Fonctionnelles (A.D.P.), Centre Hospitalier Régional et Universitaire de Lille, France; Inserm U744, Institut Pasteur de Lille, France (P.d.G., M.F., N.L., C.B.); and Faculté de Médecine de Lille, Université de Lille, France (N.L., C.B.).
Circ Heart Fail. 2014 May;7(3):434-9. doi: 10.1161/CIRCHEARTFAILURE.113.000813. Epub 2014 Feb 21.
Some patients with left ventricular systolic dysfunction (LVSD) have a dramatic improvement in left ventricular ejection fraction (LVEF) after β-blockade. No study has analyzed the long-term echocardiographic and clinical follow-up of this subgroup of patients.
We included in this analysis 174 consecutive patients with LVSD who had an LVEF≥45% after β-blockade. We performed a long-term echocardiographic follow-up (median 7.7 [4-9.9] years) and clinical follow-up (median 9.2 [7.2-10.8] years). LVEF improved from 33±8% to 54±6% after β-blockade (P<0.0001). At the last echocardiographic evaluation, 26% of the patients had an LVEF<45% (mean±SD: 34±6%), whereas 74% still had an LVEF≥45% (mean±SD: 54±6%). Independent predictors of LVEF deterioration were a low LVEF, a high left ventricular end-diastolic diameter and a low heart rate after β-blockade, and the presence of a complete left bundle-branch block. In the overall study population, survival rates were 90% at 5 years and 75% at 10 years. Cardiovascular death rate was 9%, noncardiovascular death rate was 11%, and unknown death rate was 3%. Patients with subsequent LVEF deterioration had a higher cardiovascular mortality compared with patients with sustained recovered LVEF (22% versus 4%).
The long-term survival of patients with LVSD and with near-normal LVEF after β-blockade is good. However, a quarter of these patients may experience a subsequent degradation of LVEF. These patients are at higher risk of cardiovascular mortality.
一些左心室收缩功能障碍(LVSD)患者在β受体阻滞剂治疗后左心室射血分数(LVEF)有明显改善。目前尚无研究分析该亚组患者的长期超声心动图和临床随访结果。
我们纳入了 174 例 LVSD 患者,这些患者在β受体阻滞剂治疗后 LVEF≥45%。我们进行了长期超声心动图随访(中位数 7.7[4-9.9]年)和临床随访(中位数 9.2[7.2-10.8]年)。β受体阻滞剂治疗后 LVEF 从 33±8%改善至 54±6%(P<0.0001)。最后一次超声心动图评估时,26%的患者 LVEF<45%(平均值±标准差:34±6%),而 74%的患者 LVEF 仍≥45%(平均值±标准差:54±6%)。LVEF 恶化的独立预测因素包括 LVEF 较低、左心室舒张末期直径较高、β受体阻滞剂后心率较低,以及存在完全性左束支传导阻滞。在整个研究人群中,5 年和 10 年的生存率分别为 90%和 75%。心血管死亡率为 9%,非心血管死亡率为 11%,未知死亡率为 3%。与持续恢复 LVEF 的患者相比,LVEF 随后恶化的患者心血管死亡率更高(22% vs. 4%)。
LVSD 患者在β受体阻滞剂治疗后 LVEF 接近正常,长期生存率良好。然而,四分之一的患者可能会出现 LVEF 的后续下降。这些患者心血管死亡率风险更高。